Edpm5 is one member of a group of quantitative trait loci that are responsible for the difference in susceptibility to estrogen-induced prolactinoma between the Fischer 344 (F344) and Brown Norway (BN) strains. Upon chronic estrogen treatment F344 rats develop large, hemorrhagic and invasive pituitary tumors, which exhibit both tumor angiogenesis and neoplasia. In contrast, BN rats do not develop a tumor despite an estrogen-induced increase in lactotroph density. To investigate the role of Edpm5 in the development of these tumors, we have generated a novel congenic rat strain F344.BN-Edpm5
Introduction
The rat pituitary is valuable as an experimental system for tumor biology because there is great variation between rat strains (i.e. genetic variation) in many significant tumor phenotypes. Chronic estrogen treatment of rats of the strain Fischer 344 (F344) induces large tumors, which consist primarily of lactotrophs (1, 2) . In contrast, tumor-resistant strains like Holtzman, Sprague--Dawley and Brown Norway (BN), are able to restrain estrogen-induced growth and do not form pituitary tumors (1,4--6) . Among the tumor phenotypes that are induced by chronic estrogen treatment in the pituitary of F344 rats are uncontrolled cell proliferation (4, 7) , neoplastic transformation (3, 8) , tumor angiogenesis (9--11) and (after prolonged treatment) invasion of surrounding tissue (12) . Not all investigators who have studied the estrogen-induced pituitary tumors of the F344 rat have included a tumor-resistant strain in their studies, but from those who have, we know that the processes of cell proliferation (4) and angiogenesis (2, 11) are controlled in tumor-resistant strains so that chronic estrogen treatment does not lead to either increased cell proliferation or increased angiogenesis in the tumor-resistant strains.
After chronic estrogen treatment, the pituitary of F344 rats exhibit 'tumor angiogenesis'. Tumor angiogenesis, unlike normal physiological angiogenesis, has features of uncontrolled angiogenic activity and chaotic vessel architecture (13) . Parameters of tumor angiogenesis that have been reported in the pituitary of F344 rats in response to estrogen treatment are increased microvessel count (MVC) (10, 11, 14) , loss of integrity and extensive reorganization of basement membrane (BM) (2, 3, 11) , a torturous and disorganized pattern of vasculature (11,15--17) , and loss of vessel wall integrity and the presence of vessels unlined by capillary endothelium (2, 3, 11) . In contrast, these features are all much less severe or non-existent in the pituitary of estrogen-treated BN rats (11) . Angiogenesis is a normal biological process, which is under tight control in normal tissues (18, 19) . A paradigm of modern tumor biology is the 'angiogenic switch', namely that tumor angiogenesis is controlled by a balance of many positive and negative regulatory factors and an imbalance between them is thought to cause a change to an angiogenic phenotype in tumors (20) . Thus, in comparing the angiogenic phenotype of F344 and BN after chronic estrogen treatment, we see heritable variation in the angiogenic switch and we take the view that the BN strain is proficient in controlling the angiogenic switch while the F344 strain has mutations that render it unable to control the angiogenic switch in the pituitary after chronic estrogen treatment (11) .
It should be noted that there is a significant difference between the estrogen-induced pituitary tumor of the F344 rat and human prolactinomas. It is firmly established that solid tumors are dependent on angiogenesis (13, 19) and induction of angiogenesis has been studied as a pre-neoplastic marker for solid tumors in many tissues (19,21--23) . Parameters such as increased intra-tumor microvessel density are often used to reflect this (24) , though there is some debate as to the appropriate method for counting and if it is the correct parameter for all tumor types (25) . While the F344 rat pituitary clearly shows increased angiogenic activity and higher vascular counts upon estrogen treatment (9--11,14) typical of most human solid tumors, human pituitary tumors do not exhibit increased vascularization and in fact tend to have lower vascular counts than the normal pituitary gland (26) . Thus, in this report we do not wish to represent the pituitary of the estrogen-treated F344 rat as a 'model prolactinoma', i.e. an animal model that replicates the symptoms of the specific human disease of prolactinoma. Instead, we view the angiogenic activity of the F344 rat pituitary tumor as being relevant to tumor angiogenesis in general and consistent with the phenomena seen in a broad range of solid tumors (13, 19, 24, 27) .
The difference between BN and F344 in their ability to control estrogen-induced tumor development has been found to be due to variation in at least six genes, which were identified by quantitative trail locus (QTL) mapping (28, 29) . Further mapping studies indicated that the BN allele of one of these QTL, Edpm5, is associated with a lower level of total pituitary hemoglobin (29) , MMP-9 (30) and VEGF (31) . This suggests that Edpm5 could be involved in regulating tumor angiogenesis, as both VEGF (32, 33) and MMP-9 (34, 35) are known to be involved in angiogenesis.
To delineate the effects of BN allele of the Edpm5 locus on pituitary tumor formation and tumor angiogenesis consequent to chronic estrogen stimulation, we have developed a new rat strain, the F344.BN-Edpm5 BN congenic strain, by introgressing the segment of rat Chr5 that contains the Edpm5 QTL from the BN strain into the F344 strain. Thus, by employing the F344 and F344.BN-Edpm5
BN strains in studies of the estrogen-induced pituitary tumor, we can determine the effect of Edpm5 independent of other Edpm QTL. We report here our findings on the effect of BN allele of the Edpm5 QTL on tumor angiogenesis, which were determined by analysis of the differences in tumor morphology and vasculature after chronic estrogen treatment of the F344 and F344.BN-Edpm5 BN strains. We find that the BN allele of Edpm5 locus prevents the 'angiogenic switch', which is seen in the estrogen-induced pituitary tumor in F344 rat strain. Furthermore, the BN allele of Edpm5 can block the angiogenic switch despite significant increase in mass and neoplastic transformation.
Materials and methods

Construction of the F344.BN-Edpm5
BN congenic line
To investigate the contribution of Edpm5 to the control of estrogen-dependent growth, we constructed a congenic strain in which the segment of rat Chr5 containing the Edpm5 QTL from BN was introgressed into the F344 strain. We have introgressed a segment of rat Chr5 because, at present, Edpm5 is not localized to discrete point, but to a chromosomal segment as is typical for QTL (36) . The strain was bred by what is now the standard 'speed congenic' strategy of recurrent backcrossing with selection for donor alleles of microsatellite markers across the QTL and against donor alleles on all other chromosomes (37) . Rat microsatellite markers were amplified by PCR from DNA extracted from tail biopsies and resolved by gel electrophoresis as described previously (31) . F344/NHsd (F344) and BN/SsNHsd (BN) were crossed and F 1 siblings were intercrossed. The F 2 females that were selected were homozygous for BN alleles of microsatellite markers in and around Edpm5. (This F 2 step is not typical of congenic line breeding, but was done as part of a different experiment.) Selected F 2 females were backcrossed to F344 males and their male progeny were backcrossed to F344 females. At each backcross generation, male rats were selected that were carrying a BN allele of markers including and between D5Mgh5 and D5Mit7. This interval encompasses the 2-LOD support interval of Edpm5 (28) . Of the selected males, animals were further selected for F344 alleles of microsatellites on other chromosomes. Chromosomes with known or suggested Edpm QTL (Chr 2, 3, 9 and 14) were intensively monitored with markers spaced at least 20 cM through their QTL interval. All other chromosomes were monitored with two to four markers (more markers on the larger chromosomes). This backcrossing with selection was repeated for a total of four backcross generations. The resulting congenic strain, named
F344.BN-Edpm5
BN in accordance with the guidelines of the International Rat Genome Nomenclature Committee (http://rgd.mcw.edu/nomen/rules-fornomen.shtml), is homozygous for BN alleles of microsatellite markers over the majority of rat Chr5 (Figure 1 ).
Animals and estrogen treatment
Female rats of three strains, F344, BN and F344.BN-Edpm5
BN were used in the study. Weanling female rats of F344 and BN rat strains were purchased from Harlan--Sprague--Dawley (Indianapolis, IN) and F344.BN-Edpm5
BN were bred in our colony. For chronic estrogen treatment, 21-day-old rats were given 5 mg of DES (Sigma, St Louis, MO), in Silastic tubing, implanted subcutaneously as described previously (38) to induce the pituitary tumor. Animals were killed 10 weeks after receiving the implant (5). DES is used instead of natural estrogen, such as 17-b-estradiol, because DES has a longer half-life in the body (2) . Age matched rats of each strain without implant were taken as untreated controls. Animals were housed under controlled climate, 12-h light/dark cycle, with standard chow and water ad libitum. Oakland University's Institutional Animal Care and Use Committee approved all procedures involving live animals.
Tissue sampling and preparation for microscopy After 10 weeks of estrogen treatment the rats were decapitated and their pituitaries were collected and weighed. Mass data and notation of gross morphology were collected on 20 estrogen treated and six untreated rats of each strain, and tissue from a subset of animals was used for microscopy. Three pituitaries each of the treated and control rats of all strains were fixed immediately in 2.5% glutaraldehyde and processed by embedding in epoxyaraldite for electron microscopy (EM) as described earlier (11) . Selected blocks of treated and control pituitary of each strain were sectioned at 1 mm and examined by light microscopy (LM) after staining with toluidine blue. Ultra thin sections stained with both uranyl acetate and lead citrate were then examined for blood vessel ultrastructure using a Phillips electron microscope. Three pituitaries of control rats and six of the treated rats of each strain were fixed in 4% formaldehyde for routine processing and embedding for paraffin sectioning. Paraffin-embedded tissue from control and treated animals were sectioned at 6-mm thickness and used for routine hematoxylin and eosin (H&E) stain and immunohistochemistry.
Reticulin stain
Only light microscopy was done for the histopathological classification of the tumors. EM appears to be of little or no value in the cytological diagnosis of pituitary prolactinoma as most cells fit the description of 'normal' cell type (39) . Reticulin stain was done to differentiate hyperplasia from adenoma. 
BN-Edpm5
BN congenic line is homozygous for BN allele of the marker and a white box indicates that the line was still segregating for F344 and BN alleles in the generation of rats used in this study. Genetic map distances between markers are as reported previously (31) . All microsatellite markers tested on all other chromosomes are homozygous for F344 alleles.
Gomori's reticulin stain was used according to the method described by Culling et al. (40) , as the key to distinguishing adenohypophyseal hyperplasia lies in the breakdown of reticulin network. Hyperplasia is characterized by expanded acini with an intact reticulin fiber network.
Immunohistochemical detection of prolactin (PRL) and Griffonia simplicifolia (GS) lectin
The immunohistochemical staining procedure was performed according to the technique outlined by Shull et al. (41) with modifications as described previously (11) and the additional modification of using Vector Nova-red (Vector Laboratories, Burlingame, CA) as the chromogenic substrate. Anti-rat PRL antiserum (National Hormone and Pituitary Program, NIDDK, NIH lot number AFP425-10-91) was used at 1:32 000 dilution and 20 mg/ml of biotinylated GS lectin (Vector Laboratories) was used.
Quantification of lactotroph density Quantification of lactotroph density was carried out on anti-PRL stained sections, four separate random fields were chosen as starting points and color images (600Â) were captured using a digital camera, taking care not to overlap fields. The captured images were printed out at 1440 d.p.i. on standard 11 Â 8 in, high quality photo paper. Total number of immuno-reactive lactotrophs versus non-reactive pituicytes was counted, and percentage of lactotrophs was calculated per sample. The results were averaged for each genotype.
Analysis of MVC and density
Tumor vascularity measurement was performed in order to provide a histological assessment of tumor angiogenesis. For this, the method of choice is counting MVC in areas of neoangiogenesis or 'vascular hotspots' (42, 43) . Sections probed with GS lectin, as described above, were used. MVC was calculated manually as outlined by Weidner et al. (42) , with few modifications (11) . Two areas of highest microvessel density containing the highest number of capillaries (microvessels) per area (i.e. areas of intense vascularity) were identified by light microscopy, scanning at low power (50Â and 100Â) and used for microvessel counts by consensus (J.P. and A.B. for Edpm5 Congenic rats). This was done because, due to the clonal origin of angiogenesis, angiogenic activity is confined to these neovascular 'hot spots' (42) . Large hemorrhagic regions (lakes) and regions with dilated and congested vessels and necrosis were excluded. A single countable microvessel was defined as any endothelial cell or group of cells that was clearly separate from other vessels and surrounding pituitary tissue by identifying GS lectin positivity, without the necessity of having a vessel lumen or red blood cells (RBC) within the lumen. Individual microvessels were counted at 200Â (20Â objective, 10Â eyepiece lens, 0.7386 mm 2 /field), within each hotspot identified. Data were averaged to give the MVC for each sample.
Western blot detection and quantification of VEGF Pituitary tissue used for western blots was frozen immediately after dissection and stored at À80 C. VEGF was detected in western blots as described previously (31) . The primary antibody was the anti-VEGF antibody A-20 from Santa Cruz Biotechnology (catalog # sc-152, Santa Cruz Biotechnology, Santa Cruz, CA) and was used at 1/1000 dilution. Actin was used as an internal control for protein loading and was detected with an anti-actin antibody from Sigma (catalog # A2066, Sigma-Aldrich, St Louis, MO). Secondary antibody detection was performed using the ECL Plus reagent kit and a Molecular Dynamics STORM fluorimager (Amersham Biosciences, Sunnyvale, CA). Band intensities were measured using Molecular Dynamics ImageQuant software (Amersham Biosciences). An index of VEGF level was computed as the ratio of VEGF band intensity to the intensity of the actin band within the same lane.
Statistical analysis
Significance testing was done by t-test (pairwise comparisons of MVC and lactotroph densities) and Mann--Whitney Rank sum test (pituitary mass) using SigmaStat, version 2.0 (SPSS, Chicago, IL).
Results
Effect of BN allele of Edpm5 QTL on estrogen-induced pituitary tumor growth Upon chronic estrogen treatment, the pituitaries of F344.BNEdpm5 BN rats undergo significant pituitary tumor growth, with mass increasing on average 7-fold over untreated rats. However, the tumors they develop are smaller than those developed by estrogen-treated F344 rats ( Figure 2A) .
As in the case of the F344 strain, the tumor of the estrogentreated F344.BN-Edpm5
BN rat is a prolactinoma, i.e. after extensive growth, the tissue consists primarily of prolactin positive cells ( Figure 2B--D) . Given that the F344.BNEdpm5 BN tumor is seven times normal mass and consists of 86 AE 9% lactotrophs, its growth must involve lactotroph proliferation. Consistent with what we have reported previously (11), our lactotroph density values, for both treated and untreated rats of all strains, are significantly higher than those reported by others (41, 44, 45) . We have no explanation for this, but immunohistochemistry images are provided in Figure 2 to support our counts.
As reported previously (5) Neoplasia of the pituitary tumors of F344.BN-Edpm5 BN rats The neoplastic lesions in the pituitary (adenoma, adenocarcinoma) have been described as diffuse monomorphic cell populations with loss of lobular or adenomatous areas (8) . Reticulin staining (Figure 3 ) reveals that in both estrogen-treated F344 and estrogen-treated F344.BN-Edpm5 BN rats, a true adenoma is formed and the reticulin network is completely lost in tumorous areas. Sheets of monomorphic cells are seen with broken fragments of the reticulin fibers. Normal cellular arrangement and architecture is lost with loss of normal reticulin pattern (Figure 3) .
The cellular changes seen in both of the tumor-forming strains (F344 and F344.BN-Edpm5 BN ) are detailed in Table I . Both of the tumor-forming strains show atypical neoplastic cells in addition to the monomorphic cells. These are characterized by nuclear and cellular anaplasia. There are large and hyperchromatic nuclei, nucleoli are prominent suggesting cell replication and mitotic figures are seen in concordance with earlier reports (3, 8) . Few abnormally large cells are seen. Most of the tissue proliferation is seen in the outer zone with central necrosis and fibrosis. Both F344.BN-Edpm5
BN and F344 tumors, on microscopy have areas of cellular pleomorphism and nuclear anaplasia, as well as invasion of capsule (Table I) .
Effect of the BN allele of the Edpm5 QTL on microvasculature and tumor-induced angiogenic activity Although both F344 and BN rat pituitaries have an increase in MVC upon chronic estrogen treatment, F344.BN-Edpm5
BN rat pituitaries do not (Figure 4) . Therefore, inheritance of the BN allele of the Edpm5 results in either a suppression of estrogeninduced angiogenesis, or a failure to induce angiogenesis in response to estrogen. F344 rats show a statistically significant (P 5 0.0005) increase in the MVC after treatment as reported earlier (11) . BN rats also show an increase in MVC after estrogen treatment, although the increase is of moderate statistical significance (P 5 0.05). This may correspond with tissue remodeling ongoing with the increase in lactotroph density of the BN strain (Figure 2) . We have reported previously that analysis of vessel ultrastructure shows signs of increased angiogenic activity and remodeling in the estrogentreated BN (11) .
LM shows that after 10 weeks of chronic estrogen treatment, pituitaries of F344.BN-Edpm5
BN rats show areas of necrosis along with infarction. In comparison, F344 pituitaries show dilated and congested vessels in both control and treated rats. In addition, hemorrhagic lakes are seen in estrogen-treated F344 pituitaries as reported earlier (11) . In the BN strain, the pituitaries of neither untreated nor estrogen treated rats have any significant abnormalities as seen by EM or by LM. This is despite the lactotroph hyperplasia seen post-treatment, also reported earlier (11 BN pituitary vasculature is stable with negligible remodeling activity seen. The EC has smooth abluminal boundaries with discrete well-defined BM both on capillary and parenchymal side. Capillaries have small perivascular spaces, which contain thin wavy electron dense pericytes that are in close apposition with the vessel walls and have processes intertwining with EC. In contrast, F344 capillary ultrastructure shows features of activation and ongoing vasculature remodeling or angiogenesis. There is instability of BM, with reduplication and loss at places. Pericytes are plump and separated from the capillary walls, lying in the opened up perivascular spaces. Evidence of EC and pericyte migration is present with loss of vascular integrity at places. Extravasation of RBCs into the tissue spaces is seen, suggesting an increase in permeability and Edpm5 prevents the angiogenic switch leaky vessels. EC-pericyte interaction is patchy with loss of BM between them. Intussusceptive angiogenesis is also seen in F344 pituitaries.
Estrogen-treated rats of all three genotypes show variably congested capillaries with RBCs, platelets and leukocytes. In the case of estrogen-treated F344.BN-Edpm5 BN rat pituitary tumor however, most of the capillaries do not show features pointing to significant vasculature remodeling or angiogenic activity and are similar to those in the pituitaries of untreated rats. The capillary network is less dense and typically has areas of up to eight to 10 cell thickness without interlay of capillaries. In addition to this, areas of cellular necrosis are seen, suggesting hypoxia due to lack of effective vasculature. At most places pericytes and EC are in close apposition suggesting quiescent vasculature. Some vessels with reduplication of BM and separation of pericytes are seen ( Figure 5A ), but these are a rare finding. No migrating EC and/or pericytes are seen. No significant degradation of extracellular matrix is seen outside of the necrotic areas. In contrast, pituitary tumors of estrogen-treated F344 show pronounced angiogenic activity as evidenced by organelle-rich EC, reduplication of BM is present on both capillary and parenchymal side. BM is diffuse at places and EC are seen protruding into the perivascular spaces suggesting migration. Plump organelle-rich migrating EC are seen in the pericapillary and intercellular spaces with a pericyte scaffold ( Figure 5B ). At places they throw out processes that fuse to form lumens that contain RBCs suggesting formation of new capillary lumens. Pericytes in all treated F344 pituitaries are more numerous than controls and have prominent nuclei and organelles and lie free in the perivascular space. In addition to the above, estrogen-treated F344 show microscopic lakes of RBCs bound by normal viable pituitary epithelium with no vessel wall or BM. Estrogen-treated BN pituitaries also show some angiogenic activity evidenced by EC sprouts and pericyte migration. BN also shows evidence of intussusceptive angiogenesis (11) . Thus, the F344.BNEdpm5 BN strain has the lowest grade while F344 has the most pronounced vasculature remodeling and angiogenic activity.
Effect of BN allele of Edpm5 QTL on VEGF expression
It has been reported previously that the pituitary VEGF level is increased by estrogen treatment in F344 rats (10), but not BN (31) . In the pituitary of untreated rats of both BN and F344, VEGF level was not found to be different and was barely detectable (31) . In a previous QTL mapping study, we found that a significant effect on pituitary VEGF level mapped to the same portion of rat Chr5 where the Edpm5 QTL is located with the BN alleles of these markers being associated with lowered VEGF level in pituitary of estrogen-treated rats (31) . The nature of the data collected in this earlier study necessitated the use of non-parametric statistics, which did not allow quantitative determination of the effect of the BN allele of Edpm5 on VEGF level. Now, with our congenic line, we can address this more precisely. We find that VEGF levels in estrogentreated F344.BN-Edpm5 BN rats are significantly lower than F344 after chronic estrogen treatment ( Figure 6 ). Estrogentreated F344.BN-Edpm5
BN rats do have a small increase in VEGF compared with untreated, but this difference is dwarfed by the difference between estrogen-treated and -untreated F344 ( Figure 6 ). Thus, although there are several Edpm QTL, all on different chromosomes, the presence of BN alleles of the segment of rat Chromosome 5 that contains Edpm5 reduces 490% of the estrogen-induced increase in VEGF expression that occurs in the F344 rat pituitary. VEGF level in the pituitary of untreated F344.BN-Edpm5 BN rats is undistinguishable from untreated F344 ( Figure 6 ).
As described above, the pituitary tumor of estrogen-treated F344.BN-Edpm5 BN rats is quantitatively smaller than that of F344. Therefore, to rule out the possibility that the difference in VEGF expression was merely a consequence of reduced tumor growth, we analyzed VEGF level in samples of rats for which there was great overlap in the range of pituitary mass ( Figure 6B ). In fact, the difference in average pituitary mass between the samples of BN and F344 tumors selected for VEGF analysis is not statistically significant. Despite this, there is a dramatic difference in the level of VEGF.
Discussion
The tumor susceptible F344 strain has an inherent instability of vasculature and in the presence of estrogen-induced hyperplasia readily responds by angiogenesis (2,9,11 ). In contrast, the Edpm5 prevents the angiogenic switch estrogen-treated F344.BN-Edpm5 BN rats show negligible angiogenic activity and vasculature remodeling despite incessant proliferation of lactotrophs and neoplasia. This means that introgression of the BN allele of the Edpm5 QTL into F344 not only corrects this inherent instability of vasculature, but also prevents development of the angiogenic phenotype while retaining the tumorigenic phenotype. Therefore, at least one of the genes regulating a 'switch' to angiogenic phenotype must reside at the Edpm5 QTL and the BN allele of this gene(s) confers ability to suppress angiogenesis in the presence of unabated estrogen stimulus and neoplastic transformation.
The F344.BN-Edpm5 BN rat shows a distinct phenotype from estrogen-treated rats of its parental strains, i.e. F344 (tumor susceptible rat strain) and BN (tumor-resistant strain).
F344.BN-Edpm5
BN rat pituitary tumor shows no increase in MVC [a histological measure of angiogenesis (42, 43) ] after estrogen treatment despite a significant increase in mass and eventual tissue necrosis. It is known that tumors tend to compress their blood supply and this compression can lead to cessation of blood flow in the core of the tumor leading to necrosis (19) . This appears to be true for estrogen-treated F344 rat pituitaries, where central necrosis is seen along with increased microvessel count in the peripheral areas of pituitary tumor. In the case of F344.BN-Edpm5
BN rats, however, the mechanism appears to be a true non-increase of vessels, as GS lectin histochemistry would detect compressed or collapsed blood vessels. Secondly the necrosis was not confined to the core central part only, as seen in estrogen-treated F344 rats (11) . It was seen even in the peripheral adenomatous areas. Angiogenic activity in response to estrogen treatment in the F344.BN-Edpm5
BN rat is even less than that observed in the tumor-resistant strain as judged both by MVC and analysis of ultrastructure.
The fact that the F344.BN-Edpm5 BN strain's angiogenic phenotype, based on analysis of MVC and ultrastructure, differs from both the BN and F344 strains suggests that at least a component of its effects could involve genetic interaction, i.e. epistasis. The pituitary of estrogen-treated F344.BN-Edpm5 BN rats has even less angiogenic activity than that of estrogentreated BN, even though that strain is the source of the introgressed chromosome segment. Thus, the BN allele of Edpm5 appears to be having additional phenotypic effects in a different genetic background (F344). This is, by definition, genetic interaction, though at present we do not have a mechanism for how this interaction might occur. In contrast, for the quantitative trait of pituitary mass, the lower mass of the F344.BNEdpm5 BN rat pituitary tumor compared with that of F344 is consistent with the additive quantitative effect detected previously for Edpm5 by QTL mapping in an intercross design (28) . In that QTL mapping study, which initially identified Edpm5, interaction tests were performed for the trait of pituitary mass but no statistically significant interactions were detected between Edpm5 and markers for other QTL (28) . A way to reconcile these findings is to view the BN allele of Edpm5 as having a main effect that is additive with an additional epistatic component.
Chronic estrogen treatment acting as a continuous mitogenic stimulus ensures incessant lactotroph hyperplasia (2, 3, 38) and resultant tumor formation, which is invasive (12) , in the tumor susceptible F344 strain (2, 3) . Estrogen may induce vascular proliferation required for this process either by a direct effect or indirectly. The estrogen-induced rat prolactinoma pathogenesis proceeds in two phases. In the first phase of chemical induction, estrogen acts directly on lactotrophs to stimulate growth and then in the second phase of mechanical disinhibition leads to progression (46) . This phase of progression must require and promote angiogenesis seen in pituitary tumors (17, 47, 48) , as it is well established that progression from hyperplasia to neoplasia requires the angiogenic switch in the phenotype (21,49--51) . The anterior pituitary gland contains a dense network of capillaries, almost entirely derived from the pituitary--hypothalamic portal system and does not contain any arteries (52) . Estrogen treatment of rats, however, has been shown to induce arteriogenesis derived from overlying dural vessels in tumor susceptible rats and to a small extent also in tumor-resistant rats (9) . This leads to a mechanical disinhibition (9) and along with the resultant hemodynamic changes results in angiogenic activity (53, 54 ) that leads to progression of tumor. Estrogen thus influences the anterior pituitary vasculature causing vascular reorganization or angiogenesis. This is highly pronounced in F344 (tumor susceptible) rat strain and low grade in BN (tumor resistant) rat strain (2, 11) .
Light and electron microscopy studies have shown that during angiogenesis following a stimulus for neovascularization (which in this case is estrogen-induced incessant proliferation of lactotrophs), vascular permeability increases and ECs change their morphology (55, 56) and begin to degrade their surrounding BM (56, 57) . Loss of vessel wall integrity with fragmentation and reduplication of BM is seen. This facilitates movement of cells from the intravascular compartment to perivascular spaces. Pericytes are important in the initiation and termination of angiogenesis (58, 59) and their migration to extravascular location is seen at the onset of new vessels formation (56, 60) . Pericytes from perivascular locations appear to guide newly formed sprouts through tissue (59) and finally lead to their maturation and quiescence (58) . Pituitaries of estrogen-treated F344 rats show these changes consistent with vessel remodeling and sustained angiogenesis as well as atypical vessels in response to estrogen, as described earlier (2, 11) . Extravasated RBCs are seen suggesting that vessel integrity loss must be occurring early on (2, 3, 11) . In treated BN rats the changes are not very pronounced (11) . In the case of estrogen-treated F344.BN-Edpm5 BN pituitaries, however, the ultrastructure shows negligible vasculature remodeling activity despite increase in mass and tumor formation, finally leading to tissue hypoxia and necrosis. This suggests that the F344.BN-Edpm5 BN rat strain while unable to restrain the estrogen-induced proliferative response, and thereby the adenoma formation, is able to either block or down regulate angiogenesis possibly by preventing the 'angiogenic switch'. Hence the angiogenic response is inadequate and may lead to the degenerative hypoxic effects seen in the form of cellular necrosis. Thus, in F344.BN-Edpm5
BN rats the process of neoplasia and the resultant and expected angiogenic response (seen in F344 rats) have been uncoupled.
The expression of VEGF in the pituitary of estrogen treated F344.BN-Edpm5
BN rats demonstrates that the Edpm5 region contains a major regulator of VEGF expression, though at this point we cannot determine if its effect is direct or indirect. However, the effects of Edpm5 must not be due to the mutation of the VEGF gene itself because in the rat genome the Vegf gene is present on chromosome 9 (61). Therefore Vegf can be ruled out as a candidate gene for Edpm5. This finding also suggests a mechanism for the lack of angiogenic activity in the estrogen-induced tumor of the F344.BN-Edpm5 BN strain. However, it should be noted that VEGF also promotes vascular permeability (32) , which could be relevant to the hemorrhagic lakes observed in F344 pituitary tumors (2, 3, 11) , but absent in F344.BN-Edpm5 BN pituitary tumors. A search of the rat genome of the portion of rat Chr5 that contains Edpm5 and syntenic regions in the mouse, and human genomes did not locate any compelling candidate genes, indicating that the phenotype of Edpm5 is either due to a novel gene or a gene not implicated in angiogenesis previously. The segment of rat Chr5 introgressed from BN into F344 to form our congenic line extends from near the centromere-proximal end to beyond the middle of the chromosome. Through a search in February 2004 of the Rat Genome Database (www.rgd.mcw.edu) for genes known to be on rat Chr5, and of the Mouse Genome Informatics database (www.informatics.jax.org), and Human Genome (www.ncbi.org) in regions that show synteny with rat Chr5, mouse Chr4 and human Chr9, we found several genes associated with angiogenesis. These were Id3 (62), Ece1 (63), Tek (a.k.a. Tie2) (64) , and Wasf2 (a.k.a. WAVE2) (65). Id3 and Ece1 are both on the distal end of rat Chr5 beyond the segment introgressed in our congenic line. Tek and Wasf2 are all centromere proximal to the microsatellite marker D5Mit7 and thus within the chromosomal region introgressed in our congenic line. However, they are all distal to the previously mapped support interval of Edpm5 (28, 31) .
Although the switch to an angiogenic phenotype is important to many tumor types, human pituitary adenomas are characterized by a paucity of angiogenesis and in fact have lower microvessel counts than normal pituitary tissue (26) . In this regard, the pituitary tumor of the estrogen-treated F344.BNEdpm5 BN rat with its characteristic of neoplasia without increased angiogenic activity may be a more relevant model for human prolactinoma than that of F344.
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